Anika Therapeutics (ANIK) Enterprise Value: 2010-2025
Historic Enterprise Value for Anika Therapeutics (ANIK) over the last 16 years, with Sep 2025 value amounting to $55.4 million.
- Anika Therapeutics' Enterprise Value fell 79.85% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.3 million, marking a year-over-year decrease of 899.33%. This contributed to the annual value of $161.8 million for FY2024, which is 31.61% down from last year.
- Latest data reveals that Anika Therapeutics reported Enterprise Value of $55.4 million as of Q3 2025, which was down 25.81% from $74.6 million recorded in Q2 2025.
- Anika Therapeutics' 5-year Enterprise Value high stood at $525.8 million for Q2 2021, and its period low was $55.4 million during Q3 2025.
- Moreover, its 3-year median value for Enterprise Value was $236.7 million (2023), whereas its average is $205.0 million.
- As far as peak fluctuations go, Anika Therapeutics' Enterprise Value spiked by 64.28% in 2024, and later plummeted by 79.85% in 2025.
- Over the past 5 years, Anika Therapeutics' Enterprise Value (Quarterly) stood at $393.0 million in 2021, then decreased by 20.75% to $311.5 million in 2022, then decreased by 24.02% to $236.7 million in 2023, then plummeted by 31.61% to $161.8 million in 2024, then plummeted by 79.85% to $55.4 million in 2025.
- Its Enterprise Value was $55.4 million in Q3 2025, compared to $74.6 million in Q2 2025 and $137.7 million in Q1 2025.